Emerald Health Therapeutics, Inc. (EMHTF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Emerald Health Therapeutics, Inc. (EMHTF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 40/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 18 mar 2026Emerald Health Therapeutics, Inc. (EMHTF) Resumen de Asistencia Médica y Tuberías
Emerald Health Therapeutics, Inc. is a Canadian cannabis company involved in the production, distribution, and sale of recreational and medical cannabis products. Operating as a subsidiary of Skye Bioscience, Inc., Emerald Health offers a range of cannabis products, facing strong competition in the evolving Canadian cannabis market.
Tesis de Inversión
Investing in Emerald Health Therapeutics, Inc. (EMHTF) presents a high-risk, high-reward scenario. The company's negative profit margin of -411.9% and gross margin of -66.7% indicate significant financial challenges. EMHTF operates in the competitive Canadian cannabis market, where profitability has been elusive for many players. A potential growth catalyst lies in the expansion of its product lines and market reach within Canada. However, investors should closely monitor EMHTF's financial performance and its ability to achieve sustainable profitability. The company's status as a subsidiary of Skye Bioscience, Inc. adds another layer of complexity, as its strategic direction may be influenced by its parent company. Given the current financial metrics and competitive landscape, EMHTF requires a turnaround strategy to deliver value to investors.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Negative Profit Margin: Emerald Health Therapeutics has a profit margin of -411.9%, indicating substantial losses.
- Negative Gross Margin: The company's gross margin is -66.7%, reflecting challenges in cost management and pricing.
- P/E Ratio: Emerald Health Therapeutics has a P/E ratio of -0.27, signaling that the company is currently unprofitable.
- Subsidiary Status: Emerald Health Therapeutics operates as a subsidiary of Skye Bioscience, Inc. since November 10, 2022.
- Beta: The company has a beta of 0.63, suggesting lower volatility compared to the overall market.
Competidores y Pares
Fortalezas
- Diverse product portfolio including dried cannabis, pre-rolls, oral sprays, and oils.
- Established brands such as SYNC Wellness and Emerald.
- Distribution network within the Canadian cannabis market.
- Subsidiary of Skye Bioscience, Inc., providing potential access to resources and expertise.
Debilidades
- Negative profit and gross margins indicating financial struggles.
- Dependence on the Canadian cannabis market.
- Intense competition from other licensed producers.
- Operating as a subsidiary may limit strategic autonomy.
Catalizadores
- Upcoming: Potential regulatory changes in the Canadian cannabis market that could benefit licensed producers.
- Ongoing: Expansion of product lines to include new and innovative cannabis products.
- Ongoing: Geographic expansion within Canada to reach new markets.
- Ongoing: Focus on the higher-margin medical cannabis market.
- Ongoing: Strategic partnerships and acquisitions to expand capabilities.
Riesgos
- Ongoing: Oversupply and price compression in the Canadian cannabis market.
- Ongoing: Changing regulations and consumer preferences.
- Potential: Competition from illicit cannabis producers.
- Ongoing: Potential for further financial losses due to negative profit and gross margins.
- Potential: Dependence on the Canadian cannabis market.
Oportunidades de crecimiento
- Expansion of Product Lines: Emerald Health can expand its product offerings to include new and innovative cannabis products, such as edibles, concentrates, and topicals. The market for these products is growing rapidly, driven by consumer demand for alternative consumption methods. By introducing new products, Emerald Health can attract new customers and increase its market share. The timeline for this growth opportunity is immediate, as the company can begin developing and launching new products in the near term. Success depends on effective product development and marketing strategies.
- Geographic Expansion within Canada: Emerald Health can expand its distribution network to reach new markets within Canada. This could involve partnering with retailers in provinces where the company currently has limited presence or establishing its own retail locations. Geographic expansion would allow Emerald Health to increase its sales volume and diversify its revenue streams. The timeline for this growth opportunity is medium-term, as it may take time to secure partnerships and establish new retail locations. Success depends on effective market research and strategic partnerships.
- Focus on Medical Cannabis Market: Emerald Health can focus on the medical cannabis market, which offers higher margins and greater regulatory certainty compared to the recreational market. This could involve developing cannabis-based pharmaceuticals or partnering with healthcare providers to offer cannabis-based treatments. The medical cannabis market is growing rapidly, driven by increasing awareness of the therapeutic benefits of cannabis. The timeline for this growth opportunity is long-term, as it may take time to develop new pharmaceuticals and secure regulatory approvals. Success depends on scientific research and clinical trials.
- Strategic Partnerships and Acquisitions: Emerald Health can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This could involve partnering with other cannabis companies, technology companies, or healthcare providers. Strategic partnerships and acquisitions can provide access to new technologies, markets, and expertise. The timeline for this growth opportunity is ongoing, as the company can continuously explore potential partnerships and acquisitions. Success depends on effective due diligence and integration.
- Development of Proprietary Cannabis Strains: Emerald Health can invest in research and development to develop proprietary cannabis strains with unique characteristics, such as higher potency, unique flavor profiles, or specific therapeutic benefits. Proprietary strains can provide a competitive advantage and allow the company to differentiate its products. The timeline for this growth opportunity is long-term, as it may take time to develop and stabilize new strains. Success depends on scientific expertise and effective breeding programs.
Oportunidades
- Expansion into new product categories such as edibles and concentrates.
- Geographic expansion within Canada.
- Focus on the higher-margin medical cannabis market.
- Strategic partnerships and acquisitions to expand capabilities.
Amenazas
- Oversupply and price compression in the Canadian cannabis market.
- Changing regulations and consumer preferences.
- Competition from illicit cannabis producers.
- Potential for further financial losses.
Ventajas competitivas
- Brand recognition through SYNC Wellness, fuse, Emerald, and Souvenir brands.
- Established distribution network in the Canadian cannabis market.
- Proprietary formulations for oral sprays and nano emulsion shots.
- Access to a range of cannabis strains and product formats.
Acerca de EMHTF
Emerald Health Therapeutics, Inc. was initially founded as T-Bird Pharma Inc. before rebranding in June 2015 to reflect its focus on the burgeoning cannabis industry. Headquartered in Vancouver, Canada, the company cultivates, processes, and distributes a variety of cannabis products, including dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products. These products are marketed under several brands, including SYNC Wellness, fuse, Emerald, and Souvenir. Emerald Health aims to cater to both the recreational and medical cannabis markets in Canada. However, as of November 10, 2022, Emerald Health Therapeutics operates as a subsidiary of Skye Bioscience, Inc., marking a significant shift in its corporate structure. The company's evolution reflects the dynamic nature of the cannabis industry, with Emerald Health adapting its strategy to navigate regulatory changes and evolving consumer preferences. Its product portfolio is designed to appeal to a broad spectrum of cannabis users, from those seeking traditional dried flower to those preferring more innovative consumption methods like oral sprays and nano emulsion shots.
Qué hacen
- Produces dried cannabis strains for recreational and medical use.
- Manufactures pre-rolled cannabis products for convenient consumption.
- Develops and sells oral sprays containing cannabis extracts.
- Offers nano emulsion shots for rapid cannabis absorption.
- Produces cannabis oil products for various applications.
- Markets its products under the SYNC Wellness, fuse, Emerald, and Souvenir brands.
- Distributes cannabis products through various channels in Canada.
Modelo de Negocio
- Cultivates and processes cannabis plants.
- Manufactures a range of cannabis products.
- Distributes and sells products through retail channels and partnerships.
- Generates revenue from the sale of cannabis products to recreational and medical consumers.
Contexto de la Industria
Emerald Health Therapeutics operates within the Canadian cannabis industry, which has experienced significant growth since legalization but also faces challenges such as oversupply, regulatory hurdles, and intense competition. The market includes both recreational and medical cannabis segments, with evolving consumer preferences for different product formats. Key competitors include other licensed producers who are vying for market share. Emerald Health's success depends on its ability to differentiate its products, manage costs effectively, and navigate the complex regulatory landscape. The Canadian cannabis market is projected to continue growing, driven by increasing consumer acceptance and the development of new products and distribution channels.
Clientes Clave
- Recreational cannabis consumers in Canada.
- Medical cannabis patients with prescriptions.
- Retail partners who sell Emerald Health's products.
- Wholesale distributors of cannabis products.
Finanzas
Gráfico e información
Precio de la acción de Emerald Health Therapeutics, Inc. (EMHTF): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 mar 2020
-
Stocks That Hit 52-Week Lows On Friday
· 28 feb 2020
-
Stocks That Hit 52-Week Lows On Thursday
· 27 feb 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· 26 feb 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para EMHTF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para EMHTF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de EMHTF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Información del mercado OTC de EMHTF
The OTC Other tier, where EMHTF trades, represents the lowest tier of the OTC market. Companies in this tier often face challenges in meeting minimum financial standards required for higher exchanges like NYSE or NASDAQ. These companies may be experiencing financial distress, be in early stages of development, or have chosen to remain private but still allow trading of their securities. Investing in companies on the OTC Other tier carries significant risks due to the lack of stringent listing requirements and oversight compared to major exchanges.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited Liquidity: Low trading volumes and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of Transparency: Unknown disclosure status raises concerns about the availability of financial information.
- Financial Distress: The company's negative profit and gross margins suggest potential financial challenges.
- Regulatory Risks: OTC-listed companies are subject to less regulatory oversight compared to major exchanges.
- Volatility: OTC stocks are often more volatile than those listed on major exchanges.
- Verify the availability of financial reports and other relevant information.
- Assess the company's financial health and operational performance.
- Evaluate the company's management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volumes and bid-ask spreads.
- Consult with a financial advisor before making any investment decisions.
- Operation as a subsidiary of Skye Bioscience, Inc.
- Established brands such as SYNC Wellness and Emerald.
- Distribution network within the Canadian cannabis market.
- Engagement in the regulated cannabis industry in Canada.
Preguntas Comunes Sobre EMHTF
¿Cuáles son los factores clave para evaluar EMHTF?
Emerald Health Therapeutics, Inc. (EMHTF) actualmente tiene una puntuación IA de 40/100, indicando puntuación baja. Fortaleza clave: Diverse product portfolio including dried cannabis, pre-rolls, oral sprays, and oils.. Riesgo principal a monitorear: Ongoing: Oversupply and price compression in the Canadian cannabis market.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de EMHTF?
EMHTF actualmente puntúa 40/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de EMHTF?
Los precios de EMHTF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre EMHTF?
La cobertura de analistas para EMHTF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en EMHTF?
Las categorías de riesgo para EMHTF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Oversupply and price compression in the Canadian cannabis market.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de EMHTF?
La relación P/E para EMHTF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está EMHTF sobrevalorada o infravalorada?
Determinar si Emerald Health Therapeutics, Inc. (EMHTF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de EMHTF?
Emerald Health Therapeutics, Inc. (EMHTF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data is based on the most recent available information.
- OTC market data may be limited or less reliable than data from major exchanges.
- AI analysis is pending and may provide further insights.